Illinois 2023 2023-2024 Regular Session

Illinois House Bill HB4450 Introduced / Bill

Filed 01/16/2024

                    103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4450 Introduced , by Rep. Jackie Haas SYNOPSIS AS INTRODUCED: 720 ILCS 570/208 from Ch. 56 1/2, par. 1208 Amends the Illinois Controlled Substances Act. Schedules Xylazine as a Schedule III controlled substance. LRB103 36645 RLC 66754 b   A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4450 Introduced , by Rep. Jackie Haas SYNOPSIS AS INTRODUCED:  720 ILCS 570/208 from Ch. 56 1/2, par. 1208 720 ILCS 570/208 from Ch. 56 1/2, par. 1208 Amends the Illinois Controlled Substances Act. Schedules Xylazine as a Schedule III controlled substance.  LRB103 36645 RLC 66754 b     LRB103 36645 RLC 66754 b   A BILL FOR
103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4450 Introduced , by Rep. Jackie Haas SYNOPSIS AS INTRODUCED:
720 ILCS 570/208 from Ch. 56 1/2, par. 1208 720 ILCS 570/208 from Ch. 56 1/2, par. 1208
720 ILCS 570/208 from Ch. 56 1/2, par. 1208
Amends the Illinois Controlled Substances Act. Schedules Xylazine as a Schedule III controlled substance.
LRB103 36645 RLC 66754 b     LRB103 36645 RLC 66754 b
    LRB103 36645 RLC 66754 b
A BILL FOR
HB4450LRB103 36645 RLC 66754 b   HB4450  LRB103 36645 RLC 66754 b
  HB4450  LRB103 36645 RLC 66754 b
1  AN ACT concerning criminal law.
2  Be it enacted by the People of the State of Illinois,
3  represented in the General Assembly:
4  Section 5. The Illinois Controlled Substances Act is
5  amended by changing Section 208 as follows:
6  (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)
7  Sec. 208. (a) The controlled substances listed in this
8  Section are included in Schedule III.
9  (b) Unless specifically excepted or unless listed in
10  another schedule, any material, compound, mixture, or
11  preparation which contains any quantity of the following
12  substances having a stimulant effect on the central nervous
13  system, including its salts, isomers (whether optical
14  position, or geometric), and salts of such isomers whenever
15  the existence of such salts, isomers, and salts of isomers is
16  possible within the specific chemical designation;
17  (1) Those compounds, mixtures, or preparations in
18  dosage unit form containing any stimulant substances
19  listed in Schedule II which compounds, mixtures, or
20  preparations were listed on August 25, 1971, as excepted
21  compounds under Title 21, Code of Federal Regulations,
22  Section 308.32, and any other drug of the quantitative
23  composition shown in that list for those drugs or which is

 

103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4450 Introduced , by Rep. Jackie Haas SYNOPSIS AS INTRODUCED:
720 ILCS 570/208 from Ch. 56 1/2, par. 1208 720 ILCS 570/208 from Ch. 56 1/2, par. 1208
720 ILCS 570/208 from Ch. 56 1/2, par. 1208
Amends the Illinois Controlled Substances Act. Schedules Xylazine as a Schedule III controlled substance.
LRB103 36645 RLC 66754 b     LRB103 36645 RLC 66754 b
    LRB103 36645 RLC 66754 b
A BILL FOR

 

 

720 ILCS 570/208 from Ch. 56 1/2, par. 1208



    LRB103 36645 RLC 66754 b

 

 



 

  HB4450  LRB103 36645 RLC 66754 b


HB4450- 2 -LRB103 36645 RLC 66754 b   HB4450 - 2 - LRB103 36645 RLC 66754 b
  HB4450 - 2 - LRB103 36645 RLC 66754 b
1  the same except that it contains a lesser quantity of
2  controlled substances;
3  (2) Benzphetamine;
4  (3) Chlorphentermine;
5  (4) Clortermine;
6  (5) Phendimetrazine.
7  (c) Unless specifically excepted or unless listed in
8  another schedule, any material, compound, mixture, or
9  preparation which contains any quantity of the following
10  substances having a potential for abuse associated with a
11  depressant effect on the central nervous system:
12  (1) Any compound, mixture, or preparation containing
13  amobarbital, secobarbital, pentobarbital or any salt
14  thereof and one or more other active medicinal ingredients
15  which are not listed in any schedule;
16  (2) Any suppository dosage form containing
17  amobarbital, secobarbital, pentobarbital or any salt of
18  any of these drugs and approved by the Federal Food and
19  Drug Administration for marketing only as a suppository;
20  (3) Any substance which contains any quantity of a
21  derivative of barbituric acid, or any salt thereof:
22  (3.1) Aprobarbital;
23  (3.2) Butabarbital (secbutabarbital);
24  (3.3) Butalbital;
25  (3.4) Butobarbital (butethal);
26  (4) Chlorhexadol;

 

 

  HB4450 - 2 - LRB103 36645 RLC 66754 b


HB4450- 3 -LRB103 36645 RLC 66754 b   HB4450 - 3 - LRB103 36645 RLC 66754 b
  HB4450 - 3 - LRB103 36645 RLC 66754 b
1  (5) Methyprylon;
2  (6) Sulfondiethylmethane;
3  (7) Sulfonethylmethane;
4  (8) Sulfonmethane;
5  (9) Lysergic acid;
6  (10) Lysergic acid amide;
7  (10.1) Tiletamine or zolazepam or both, or any salt of
8  either of them.
9  Some trade or other names for a tiletamine-zolazepam
10  combination product: Telazol.
11  Some trade or other names for Tiletamine:
12  2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
13  Some trade or other names for zolazepam:
14  4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
15  [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
16  (11) Any material, compound, mixture or preparation
17  containing not more than 12.5 milligrams of pentazocine or
18  any of its salts, per 325 milligrams of aspirin;
19  (12) Any material, compound, mixture or preparation
20  containing not more than 12.5 milligrams of pentazocine or
21  any of its salts, per 325 milligrams of acetaminophen;
22  (13) Any material, compound, mixture or preparation
23  containing not more than 50 milligrams of pentazocine or
24  any of its salts plus naloxone HCl USP 0.5 milligrams, per
25  dosage unit;
26  (14) Ketamine;

 

 

  HB4450 - 3 - LRB103 36645 RLC 66754 b


HB4450- 4 -LRB103 36645 RLC 66754 b   HB4450 - 4 - LRB103 36645 RLC 66754 b
  HB4450 - 4 - LRB103 36645 RLC 66754 b
1  (15) Thiopental; .
2  (16) Xylazine: (N-2,6-dimethylpheny1)-5,6-
3  dihydro-4H-1,3 thiazin-2-amine), including its isomers,
4  esters, ethers, salts, and salts of isomers, esters, and
5  ethers, whenever the existence of such isomers, esters,
6  ethers, and salts is possible within the specific chemical
7  designation.
8  (d) Nalorphine.
9  (d.5) Buprenorphine.
10  (e) Unless specifically excepted or unless listed in
11  another schedule, any material, compound, mixture, or
12  preparation containing limited quantities of any of the
13  following narcotic drugs, or their salts calculated as the
14  free anhydrous base or alkaloid, as set forth below:
15  (1) not more than 1.8 grams of codeine per 100
16  milliliters or not more than 90 milligrams per dosage
17  unit, with an equal or greater quantity of an isoquinoline
18  alkaloid of opium;
19  (2) not more than 1.8 grams of codeine per 100
20  milliliters or not more than 90 milligrams per dosage
21  unit, with one or more active non-narcotic ingredients in
22  recognized therapeutic amounts;
23  (3) (blank);
24  (4) (blank);
25  (5) not more than 1.8 grams of dihydrocodeine per 100
26  milliliters or not more than 90 milligrams per dosage

 

 

  HB4450 - 4 - LRB103 36645 RLC 66754 b


HB4450- 5 -LRB103 36645 RLC 66754 b   HB4450 - 5 - LRB103 36645 RLC 66754 b
  HB4450 - 5 - LRB103 36645 RLC 66754 b
1  unit, with one or more active, non-narcotic ingredients in
2  recognized therapeutic amounts;
3  (6) not more than 300 milligrams of ethylmorphine per
4  100 milliliters or not more than 15 milligrams per dosage
5  unit, with one or more active, non-narcotic ingredients in
6  recognized therapeutic amounts;
7  (7) not more than 500 milligrams of opium per 100
8  milliliters or per 100 grams, or not more than 25
9  milligrams per dosage unit, with one or more active,
10  non-narcotic ingredients in recognized therapeutic
11  amounts;
12  (8) not more than 50 milligrams of morphine per 100
13  milliliters or per 100 grams with one or more active,
14  non-narcotic ingredients in recognized therapeutic
15  amounts.
16  (f) Anabolic steroids, except the following anabolic
17  steroids that are exempt:
18  (1) Androgyn L.A.;
19  (2) Andro-Estro 90-4;
20  (3) depANDROGYN;
21  (4) DEPO-T.E.;
22  (5) depTESTROGEN;
23  (6) Duomone;
24  (7) DURATESTRIN;
25  (8) DUO-SPAN II;
26  (9) Estratest;

 

 

  HB4450 - 5 - LRB103 36645 RLC 66754 b


HB4450- 6 -LRB103 36645 RLC 66754 b   HB4450 - 6 - LRB103 36645 RLC 66754 b
  HB4450 - 6 - LRB103 36645 RLC 66754 b
1  (10) Estratest H.S.;
2  (11) PAN ESTRA TEST;
3  (12) Premarin with Methyltestosterone;
4  (13) TEST-ESTRO Cypionates;
5  (14) Testosterone Cyp 50 Estradiol Cyp 2;
6  (15) Testosterone Cypionate-Estradiol Cypionate
7  injection; and
8  (16) Testosterone Enanthate-Estradiol Valerate
9  injection.
10  (g) Hallucinogenic substances.
11  (1) Dronabinol (synthetic) in sesame oil and
12  encapsulated in a soft gelatin capsule in a U.S. Food and
13  Drug Administration approved product. Some other names for
14  dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
15  6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
16  (-)-delta-9-(trans)-tetrahydrocannabinol.
17  (2) (Reserved).
18  (h) The Department may except by rule any compound,
19  mixture, or preparation containing any stimulant or depressant
20  substance listed in subsection (b) from the application of all
21  or any part of this Act if the compound, mixture, or
22  preparation contains one or more active medicinal ingredients
23  not having a stimulant or depressant effect on the central
24  nervous system, and if the admixtures are included therein in
25  combinations, quantity, proportion, or concentration that
26  vitiate the potential for abuse of the substances which have a

 

 

  HB4450 - 6 - LRB103 36645 RLC 66754 b


HB4450- 7 -LRB103 36645 RLC 66754 b   HB4450 - 7 - LRB103 36645 RLC 66754 b
  HB4450 - 7 - LRB103 36645 RLC 66754 b

 

 

  HB4450 - 7 - LRB103 36645 RLC 66754 b